Long-term Results of the Pediatric Oncology Group Studies for Childhood Acute Lymphoblastic Leukemia 1984-2001: a Report from the Children's Oncology Group

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2009 Dec 18

PMID 20016527

Citations 89

Authors

W L Salzer

M Devidas

W L Carroll

N Winick

J Pullen

S P Hunger

B A Camitta

Affiliations

Soon will be listed here.

Abstract

From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies. Ten-year event-free survival (EFS) for patients >12 months of age with B-precursor ALL on acute leukemia in children 14, 15 and 16 series were 66.7+/-1.2%, 68.1+/-1.4% and 73.2+/-2.1%, respectively. Intermediate dose methotrexate (ID MTX; 1 g/m(2)) improved outcomes for standard risk patients (10-year EFS 77.5+/-2.7% vs 66.3+/-3.1% for oral MTX). Neither MTX intensification (2.5 g/m(2)) nor addition of cytosine arabinoside/daunomycin/teniposide improved outcomes for higher risk patients. Intermediate dose mercaptopurine (1 g/m(2)) failed to improve outcomes for either group. Ten-year EFS for patients with T-cell ALL, POG 8704 and 9404 were 49.1+/-3.1% and 72.2+/-4.7%, respectively. Intensive asparaginase (10-year EFS 61.8 vs 42.7%) and high-dose MTX (5 g/m(2)) (10-year EFS 78.0 vs 65.8%) improved outcomes. There was a non-significant improvement in EFS for infants (10-year EFS 17.7+/-7.2-31.9+/-8.3%). Prognostic indicators for B-precursor ALL were age and WBC at diagnosis, gender, central nervous system disease, DNA index and cytogenetic abnormalities. Only gender was prognostic in T-cell ALL. In infants, WBC and MLL translocation were linked to inferior outcome.

Citing Articles

New insights into mitochondrial quality control in anthracycline-induced cardiotoxicity: molecular mechanisms, therapeutic targets, and natural products.

Li W, Zhang Y, Wei Y, Ling G, Zhang Y, Li Y Int J Biol Sci. 2025; 21(2):507-523.

PMID: 39781459 PMC: 11705644. DOI: 10.7150/ijbs.103810.

Cerebrospinal Fluid Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study in China.

Tu S, Zhang K, Liu C, Wang N, Chu J, Yang L Cancer Med. 2024; 13(23):e70452.

PMID: 39651721 PMC: 11626476. DOI: 10.1002/cam4.70452.

Primary Protection of Diosmin Against Doxorubicin Cardiotoxicity via Inhibiting Oxido-Inflammatory Stress and Apoptosis in Rats.

Abohashem R, Ahmed H, Sayed A, Effat H Cell Biochem Biophys. 2024; 82(2):1353-1366.

PMID: 38743136 DOI: 10.1007/s12013-024-01289-7.

Cardiac Autonomic and Endothelial Function in Acute Lymphoblastic Leukaemia Patients Immediately After Chemotherapy and at the Three-Month Follow-up.

Sameer S, N P, Kuppusamy S, Adole P, Kayal S Cureus. 2024; 16(2):e55108.

PMID: 38558679 PMC: 10979077. DOI: 10.7759/cureus.55108.

[Impact of acute lymphoblastic leukemia on the microbiome and oral lesions: scoping review].

Garcia Rico O, Medina J, Sanchez Becerra E, Cepeda Bravo J, Tejeda Nava F, Rocha Viggiano A Rev Cient Odontol (Lima). 2024; 10(4):e131.

PMID: 38390612 PMC: 10880714. DOI: 10.21142/2523-2754-1004-2022-131.

References

Steuber C, LEVY G, Nix W, SHEPHERD D, Starling K, Fernbach D . Use of L-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia. Med Pediatr Oncol. 1978; 5(1):33-8. DOI: 10.1002/mpo.2950050105. View

Hunger S, Lu X, Devidas M, Camitta B, Gaynon P, Winick N . Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012; 30(14):1663-9. PMC: 3383113. DOI: 10.1200/JCO.2011.37.8018. View

Smith M, Arthur D, Camitta B, Carroll A, Crist W, Gaynon P . Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996; 14(1):18-24. DOI: 10.1200/JCO.1996.14.1.18. View

Mahoney Jr D, Shuster J, Nitschke R, Lauer S, Winick N, Steuber C . Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology.... J Clin Oncol. 1998; 16(1):246-54. DOI: 10.1200/JCO.1998.16.1.246. View

Clavell L, Gelber R, Cohen H, Cassady J, Tarbell N, Blattner S . Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986; 315(11):657-63. DOI: 10.1056/NEJM198609113151101. View

Seibel N, Steinherz P, Sather H, Nachman J, Delaat C, Ettinger L . Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2007; 111(5):2548-55. PMC: 2254538. DOI: 10.1182/blood-2007-02-070342. View

Lauer S, Camitta B, Leventhal B, Mahoney Jr D, Shuster J, Kiefer G . Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study. J Pediatr Hematol Oncol. 1998; 20(3):229-33. DOI: 10.1097/00043426-199805000-00008. View

Winick N, Shuster J, Bowman W, Borowitz M, Farrow A, Jacaruso D . Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol. 1996; 14(10):2803-11. DOI: 10.1200/JCO.1996.14.10.2803. View

Mullighan C, Downing J . Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia. 2009; 23(7):1209-18. DOI: 10.1038/leu.2009.18. View

10.

Harris M, Shuster J, Pullen J, Borowitz M, Carroll A, Behm F . Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study. Leukemia. 2000; 14(9):1570-6. DOI: 10.1038/sj.leu.2401886. View

11.

Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig W, Henze G . Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia. 2001; 14(12):2205-22. DOI: 10.1038/sj.leu.2401973. View

12.

Real P, Ferrando A . NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia. 2009; 23(8):1374-7. PMC: 2814171. DOI: 10.1038/leu.2009.75. View

13.

Mahoney Jr D, Shuster J, Nitschke R, Lauer S, Steuber C, Winick N . Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. J Clin Oncol. 1998; 16(5):1712-22. DOI: 10.1200/JCO.1998.16.5.1712. View

14.

Lauer S, Pinkel D, Buchanan G, SARTAIN P, CORNET J, Krance R . Cytosine arabinoside/cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia. Potential selective effect in T-cell leukemia. Cancer. 1987; 60(10):2366-71. DOI: 10.1002/1097-0142(19871115)60:10<2366::aid-cncr2820601003>3.0.co;2-u. View

15.

Pui C, Relling M, Behm F, Hancock M, Boyett J, Raimondi S . L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia. 1995; 9(10):1680-4. View

16.

Nguyen K, Devidas M, Cheng S, La M, Raetz E, Carroll W . Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008; 22(12):2142-50. PMC: 2872117. DOI: 10.1038/leu.2008.251. View

17.

Andersson A, Ritz C, Lindgren D, Eden P, Lassen C, Heldrup J . Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia. 2007; 21(6):1198-203. DOI: 10.1038/sj.leu.2404688. View

18.

Harris M, Shuster J, Carroll A, Look A, Borowitz M, Crist W . Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood. 1992; 79(12):3316-24. View

19.

Chauvenet A, Martin P, Devidas M, Linda S, Bell B, Kurtzberg J . Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood. 2007; 110(4):1105-11. PMC: 1939894. DOI: 10.1182/blood-2006-12-061689. View

20.

Bostrom B, Sensel M, Sather H, Gaynon P, La M, Johnston K . Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003; 101(10):3809-17. DOI: 10.1182/blood-2002-08-2454. View